Tumefactive multiple sclerosis lesions under fingolimod treatment
نویسندگان
چکیده
منابع مشابه
Fingolimod treatment in multiple sclerosis
Objective: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume. Methods: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingo...
متن کاملTumefactive multiple sclerosis plaque.
W e present a case of a large solitary demyelinating plaque in the brain masquerading as tumour. A 34 year old healthy woman presented with sudden onset of left hemiparesis. Subsequent MRI of the brain showed a single large 2.5 cm right sided enhancing lesion within the white matter of the parietal lobe (fig 1). The lesion appeared to originate from the corpus callosum. Diffusion weighted and g...
متن کاملDominant perivenular enhancement of tumefactive demyelinating lesions in multiple sclerosis.
A 51-year-old woman presented with aphasia and bifrontal MRI lesions with punctuate and vague linear enhancement (figure). She improved spontaneously but 4 months later deteriorated due to the large mass and required cranial decompression. Innumerable, perivenular enhancements perpendicular to the lateral ventricles were seen within extensive bihemispheric white matter lesions. Multiple scleros...
متن کاملTumefactive Multiple Sclerosis in Taiwan
BACKGROUND Multiple sclerosis (MS) is less common in Asia, including Taiwan, and some characteristics of MS in Asians differ from those of Caucasians. Tumefactive brain lesion is even rarer in MS patients. OBJECTIVE To review patients with tumefactive MS and compare them with those in other studies investigating tumefactive demyelinating lesions and our Taiwanese typical MS patients. METHOD...
متن کاملFingolimod and multiple sclerosis
Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2012
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0b013e3182735cb3